BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
See today's BioWorld
Home
» MACK Keeps on Trucking, While Deal with Actavis Sweetens Clinic Failure
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
MACK Keeps on Trucking, While Deal with Actavis Sweetens Clinic Failure
Nov. 27, 2013
By
Randy Osborne
No Comments
Oncology partner Sanofi SA likely was not thrilled by the clinical part of the mixed bag of news offered by Merrimack Pharmaceuticals Inc., but a moderate-sized nanoliposomal deal with specialty pharma Actavis plc made Wall Street happy.
BioWorld